913388-55-3

Basic information

• Product Name: 1H-Indole-1-carboxylic acid, 2-borono-5-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]carbonyl]-, 1-(1,1-dimethylethyl) ester
• Synonyms: 1H-Indole-1-carboxylic acid, 2-borono-5-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]carbonyl]-, 1-(1,1-dimethylethyl) ester;LVGLYSZJALKNOQ-UHFFFAOYSA-N
• CAS NO: 913388-55-3
• Molecular Formula: C23H32BN3O7
• Molecular Weight: 473.33
• Mol File: 913388-55-3.mol

Chemical Properties

• Boiling Point: 658°C at 760 mmHg
• Flash Point: 351.7°C
• Appearance: /
• Density: 1.24g/cm³
• Vapor Pressure: 3.28E-18mmHg at 25°C
• Refractive Index: 1.571
• CAS DataBase Reference: 1H-Indole-1-carboxylic acid, 2-borono-5-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]carbonyl]-, 1-(1,1-dimethylethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole-1-carboxylic acid, 2-borono-5-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]carbonyl]-, 1-(1,1-dimethylethyl) ester(913388-55-3)
• EPA Substance Registry System: 1H-Indole-1-carboxylic acid, 2-borono-5-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]carbonyl]-, 1-(1,1-dimethylethyl) ester(913388-55-3)

Safety Data

• Hazardous Substances Data: 913388-55-3(Hazardous Substances Data)

Usage

Molecular structure

A complex compound consisting of an indole ring, a boron atom, and various functional groups such as carbonyl, ester, and piperazine rings.

Boronic acid derivative

Bortezomib is derived from boronic acid, which contributes to its unique chemical properties and biological activity.

Proteasome inhibitor

Bortezomib is a reversible inhibitor of the 26S proteasome, an enzyme complex responsible for degrading damaged or misfolded proteins in cells.

Anticancer activity

Bortezomib is commonly used in the treatment of multiple myeloma and mantle cell lymphoma, as it inhibits the action of proteasomes, leading to the death of cancer cells.

Administration route

Bortezomib is administered intravenously, allowing for direct delivery into the bloodstream.

Side effects

Some potential side effects of Bortezomib include peripheral neuropathy, thrombocytopenia, and gastrointestinal symptoms.

Efficacy

Despite its side effects, Bortezomib has shown significant efficacy in the treatment of multiple myeloma and mantle cell lymphoma, improving patient outcomes.

InChI:InChI=1/C23H32BN3O7/c1-22(2,3)33-20(29)26-11-9-25(10-12-26)19(28)15-7-8-17-16(13-15)14-18(24(31)32)27(17)21(30)34-23(4,5)6/h7-8,13-14,31-32H,9-12H2,1-6H3

Relevant articles and documents

JAK INHIBITOR

A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) {wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.